2 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine - Malignancy, Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Cyteir Therapeutics, Inc. | 169 | 2019-10-09 | 2024-12-24 |
| Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers IONIS-STAT3Rx - Advanced Cancers, DLBCL | Phase 1 / Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 64 | 2012-02-27 | 2018-06-25 |
Breast Neoplasms (1) · Head and Neck Neoplasms (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Adnexal Diseases (1) · Blood Protein Disorders (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Cardiovascular Diseases (1) · Digestive System Diseases (1)
Bendamustine Hydrochloride (1) · Capecitabine (1) · Gemcitabine (1) · Rituximab (1)
Cyteir Therapeutics, Inc. (1) · Ionis Pharmaceuticals, Inc. (1)
United States (2)
Markus Renschler, MD (1) · Steve Hughes, MD (1)